Instructions for Upatinib: Learn more about the usage, dosage, precautions, contraindications and other information of Upatinib.

Drug name

Generic name: Upadacitinib (Upadacitinib)

Product name:Rinvoq

Dosage form: oral tablet

Drug Classification

Upadatinib is a Janus kinase (JAK) inhibitor used to treat inflammatory diseases caused by the immune system. It slows down the immune response by selectively inhibiting JAK1 and is mainly used to treat rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis and other diseases.

Indications

Upadatinib is mainly used to treat the following diseases:

1.Rheumatoid arthritis (RA): used for the treatment of moderately to severely active rheumatoid arthritis in adults, especially patients who are ineffective or intolerant to anti-TNF-α drugs.

2.Ulcerative colitis (UC): used to treat active ulcerative colitis in adults.

3.Ankylosing spondylitis (AS): used to treat adult patients with ankylosing spondylitis.

4. Other immune system-related diseases: Upadatinib has also been studied to treat other immune diseases such as psoriasis. Specific indications need to be based on the guidance of a doctor.

Usage and dosage

Upadatinib is an oral medication, usually taken once daily. The specific dosage depends on the disease being treated and the patient's specific condition:

1.Rheumatoid arthritis: The recommended dose is 15mg once a day. The dose can be adjusted according to clinical response in the early stage of treatment. The maximum recommended dose is 30mg/day.

2.Ulcerative colitis: The recommended dose is30mgonce daily. Adjustments can be made based on clinical efficacy.

3.Ankylosing spondylitis: the recommended dose is15mgOnce a day. Dosage adjustments may be made based on clinical response.

In terms of food intake, upadatinib is not affected by food and can be taken with food or on an empty stomach. If a dose is missed, the patient should take it as soon as possible, but if it is close to the next dose, the missed dose should be skipped and the next dose should be taken at the normal time.

Contraindications

Upadatinib is not suitable for use in the following conditions:

Patients with known hypersensitivity to upadacitinib or any of its components.

1.Active tuberculosis infection: Due to its immunosuppressive effect, upadatinib may increase the risk of infection, therefore, patients with active tuberculosis infection should avoid its use.

2.Severe hepatic insufficiency: Upadatinib is metabolized by the liver, so patients with severe hepatic insufficiency should avoid using this drug.

Warnings and Precautions

3.Risk of infection: Upadatinib may suppress the immune response and increase the risk of infections such as bacteria, fungi, viruses and tuberculosis. During treatment, patients need to be closely monitored for symptoms of infection, especially lung and urinary tract infections.

4. Hematology monitoring: Regular blood routine examinations are required during the use of Upatinib, including monitoring of white blood cells, red blood cell counts, platelets and other indicators, because the drug may cause side effects such as anemia, leukopenia or thrombocytopenia.

5. Liver function monitoring: Since upadatinib is metabolized by the liver, liver function needs to be monitored regularly during treatment, especially in patients with abnormal liver function. If liver enzyme elevations are significant, dose adjustment or discontinuation should be considered.

6.Vaccination: Before starting treatment with upadacitinib, ensure that the patient has received all routine vaccinations. Vaccination should be done before treatment because immunosuppressive drugs may reduce the effectiveness of the vaccine.

side effects

1.Common side effects include:

Infections: Upper respiratory tract infection, urinary tract infection, shingles, etc.

Digestive system: nausea, diarrhea, gastrointestinal discomfort, etc.

Skin reactions: rash, itching, etc.

Hematological reactions: anemia, leukopenia, etc.

2.Serious side effects include:

Thrombotic diseases such as deep vein thrombosis and pulmonary embolism.

Serious infections such as tuberculosis, pneumonia, etc.

Acute hepatic insufficiency.

For use by special groups

1.Pregnant and lactating women: The safety of upadatinib has not been fully verified in pregnant and lactating women. Therefore, this medicine should not be used by pregnant and breastfeeding women unless clearly necessary.

2.Children and Adolescents: There is currently insufficient clinical data to support the use of upadatinib in children and adolescents under the age of 18.

Upadatinib, as a JAK inhibitor, can effectively regulate the immune system response and help alleviate a variety of immune system-related diseases, such as rheumatoid arthritis, ulcerative colitis and ankylosing spondylitis. However, it comes with certain side effects and risks, especially in immunocompromised patients. It needs to be used under the guidance of a doctor, monitored regularly, and the dosage adjusted according to the patient's specific condition.

Reference materials:https://www.rinvoq.com/